Capricor Therapeutics (CAPR) Other Non-Current Liabilities (2012 - 2014)
Capricor Therapeutics' (CAPR) quarterly Other Non-Current Liabilities came in at $11.3 million in Q1 2014, up 182.02% quarter-over-quarter from $4.0 million in Q4 2013.
Capricor Therapeutics (CAPR) Other Non-Current Liabilities (2012 - 2014) Analysis & Trends
Capricor Therapeutics' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $11.3 million for Q1 2014.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $11.3 million in Q1 2014; TTM through Mar 2014 was $11.3 million, a N/A change from a year earlier, with the FY2013 full-year figure at $4.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities rose to $11.3 million in Q1 2014 per CAPR's latest filing, from $4.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $11.3 million in Q1 2014 and bottomed at $190863.0 in Q2 2012.
- The 3-year median for Other Non-Current Liabilities is $4.0 million (2013), against an average of $5.2 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 11.34 Mn |
| Dec 31, 2013 | 4.02 Mn |
| Jun 30, 2012 | 190,863.00 |